Zolmitriptan oral dispersible film

Drug Profile

Zolmitriptan oral dispersible film

Alternative Names: zolmitriptan ODF; Zolmitriptan PharmaFilm; Zolmitriptan RapidFilm; Zolmitriptan Renantos 2.5mg Schmelzfilm; Zolmitriptan Renantos 5mg Schmelzfilm

Latest Information Update: 25 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator APR Applied Pharma Research; Labtec
  • Developer APR Applied Pharma Research; MonoSol Rx; tesa Labtec
  • Class Antimigraines; Oxazolidinones; Small molecules; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 17 Apr 2015 Zolmitriptan oral dispersible film is approved in the European Union for Migraine
  • 08 Feb 2012 Registered for Migraine in Austria (PO)
  • 08 Feb 2012 Registered for Migraine in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top